120 related articles for article (PubMed ID: 8280493)
1. Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II.
Lorico A; Long BH
Eur J Cancer; 1993; 29A(14):1985-91. PubMed ID: 8280493
[TBL] [Abstract][Full Text] [Related]
2. Chartreusin, elsamicin A and related anti-cancer antibiotics.
Portugal J
Curr Med Chem Anticancer Agents; 2003 Nov; 3(6):411-20. PubMed ID: 14529449
[TBL] [Abstract][Full Text] [Related]
3. Activity of a chartreusin analog, elsamicin A, on breast cancer cells.
Silvestrini R; Sanfilippo O; Zaffaroni N; De Marco C; Catania S
Anticancer Drugs; 1992 Dec; 3(6):677-81. PubMed ID: 1288737
[TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanism of actin of gilvocarcin V and chrysomycin A.
Wei TT; Byrne KM; Warnick-Pickle D; Greenstein M
J Antibiot (Tokyo); 1982 Apr; 35(4):545-8. PubMed ID: 7096212
[No Abstract] [Full Text] [Related]
5. Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.
Umemura K; Yanase K; Suzuki M; Okutani K; Yamori T; Andoh T
Biochem Pharmacol; 2003 Aug; 66(3):481-7. PubMed ID: 12907247
[TBL] [Abstract][Full Text] [Related]
6. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
7. Influence of elsamicin A on the activity of mammalian topoisomerase I.
Rodríguez-Campos A; Azorín F; Portugal J
Biochemistry; 1996 Aug; 35(34):11177-82. PubMed ID: 8780522
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
[TBL] [Abstract][Full Text] [Related]
9. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.
Hanada M; Mizuno S; Fukushima A; Saito Y; Noguchi T; Yamaoka T
Jpn J Cancer Res; 1998 Nov; 89(11):1229-38. PubMed ID: 9914793
[TBL] [Abstract][Full Text] [Related]
10. Selective DNA cleavage by elsamicin A and switch function of its amino sugar group.
Uesugi M; Sekida T; Matsuki S; Sugiura Y
Biochemistry; 1991 Jul; 30(27):6711-5. PubMed ID: 1648389
[TBL] [Abstract][Full Text] [Related]
11. Light-induced modifications of DNA by gilvocarcin V and its aglycone.
Tse-Dinh YC; McGee LR
Biochem Biophys Res Commun; 1987 Mar; 143(3):808-12. PubMed ID: 3566756
[TBL] [Abstract][Full Text] [Related]
12. Photosensitized DNA breaks and DNA-to-protein crosslinks induced in human cells by antitumor agent gilvocarcin V.
Peak MJ; Peak JG; Blaumueller CM; Elespuru RK
Chem Biol Interact; 1988; 67(3-4):267-74. PubMed ID: 3191537
[TBL] [Abstract][Full Text] [Related]
13. Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
Konishi M; Sugawara K; Kofu F; Nishiyama Y; Tomita K; Miyaki T; Kawaguchi H
J Antibiot (Tokyo); 1986 Jun; 39(6):784-91. PubMed ID: 3733527
[TBL] [Abstract][Full Text] [Related]
14. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
15. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
[TBL] [Abstract][Full Text] [Related]
16. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
18. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
[TBL] [Abstract][Full Text] [Related]
20. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
